Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience

Abstract

Objective: The aim of this study was to identify the clinical features
 and prognostic factors of cancer patients with leptomeningeal
 carcinomatosis (LMC) in a single center.
 Patients and Methods: Patients 18 and older who had
 LMC diagnosis between 2013 and 2018 at Medical Oncology
 Department, Antalya Education and Research Hospital, Health
 Sciences University were included into the study. Their clinical
 features, treatment approaches, overall survival, survival after LMC
 diagnosis and prognostic factors on survival were retrospectively
 investigated.
 Results: Sixteen solid cancer patients included in the study.
 The median time from primary tumor diagnosis to LMC diagnosis
 was 6 months (range, 1-180 months). The median time from LMC
 diagnosis to death was 1.5 months (range, 1-14 months). The
 median overall survival for the entire population was 11 months
 (95%CI 5.7-16.3). Age (p=0.6), gender (p=0.51), metastases areas
 (for liver metastases p=0.95, for lung metastases p=0.26, for bone
 metastases p=0.82), The Eastern Cooperative Oncology Group
 Performance Status ( ECOG PS) (p=0.18), treatment type of LMC
 (only radiation therapy (RT) p=0.33; RT followed by intrathecal
 methotrexate (IT MTX) (p=0.35), RT type (p=0.76) and time from
 primary tumor diagnosis to LMC diagnosis (p=0.50) did not show
 prognostic effect on overall survival after LMC diagnosis.
 Conclusion: Overall survival after LMC diagnosis is too short
 to see the effect of treatment modalities. Our study did not find any
 favorable or unfavorable prognostic factor on survival after LMC
 diagnosis.